IGFBP7 Antibodies

Structure of IGFBP7

IGFBP7 is a secreted glycoprotein with a molecular weight of approximately 29 kDa. The molecular weight varies slightly among different species due to differences in the level of glycosylation modification.

This protein is composed of approximately 250 amino acids, and its spatial structure depends on a rigid core formed by conserved cysteine residues. The structural core contains an insulin-like growth factor binding domain, which, through specific β-sheets and α-helices, forms a hydrophobic pocket for ligand binding. A crucial "cell adhesion module" is located at the C-terminal end, mediating interactions with extracellular matrix components, which is the structural basis for its non-IGF-dependent functions.

Fig. 1 Diagram shows proposed IGFBP7 action in the stress myocardium.¹

Key structural properties of IGFBP7:

• Secretory glycoprotein, containing insulin-like growth factor binding domain (IB domain)
• The core structure is stabilized by a network of disulfide bonds formed by conserved cysteine residues
• The unique "Kazal-like domain" mediates its interaction with the extracellular matrix and cell surfaces
• The C-terminal region contains a functional "cell adhesion motif" responsible for IGF-independent signaling regulation

Functions of IGFBP7

The main function of the IGFBP7 gene is to regulate the biological activity of insulin-like growth factors (IGFs) by binding to them, and to participate in the regulation of cell proliferation and aging. In addition, it also plays a key role independently of the IGF pathway in tumor suppression, angiogenesis, and cell adhesion.

Unlike typical members of the IGFBP family, IGFBP7 has a relatively lower affinity for IGFs, but its functions are more pleiotropic. It plays a complex and crucial role in the regulation of the tumor microenvironment and tissue homeostasis.

Applications of IGFBP7 and IGFBP7 Antibody in Literature

1. Zhang, Liyong, et al. "Insulin-like growth factor-binding protein-7 (IGFBP7) links senescence to heart failure." Nature Cardiovascular Research 1.12 (2022): 1195-1214. https://doi.org/10.1038/s44161-022-00181-y

The article indicates that in the research on heart failure, the increased expression of IGFBP7 promotes myocardial aging. Mechanistically, IGFBP7 inhibits FOXO3a, thereby weakening DNA repair and antioxidant capacity, and exacerbating cardiac damage. Targeted inhibition of IGFBP7 can delay the progression of heart failure and has therapeutic potential.

2. Yi, Xianyanling, et al. "IGFBP7 and the tumor immune landscape: a novel target for immunotherapy in bladder cancer." Frontiers in Immunology 13 (2022): 898493. https://doi.org/10.3389/fimmu.2022.898493

The article indicates that in bladder cancer, high expression of IGFBP7 is associated with adverse clinical features. It promotes lymphocyte infiltration but inhibits T-cell recognition and killing functions, resulting in a reduced immune treatment response. Studies have shown that targeting IGFBP7 has the potential to become a new strategy for combined immunotherapy in bladder cancer.

3. Chen, Zhe, et al. "Exercise protects proliferative muscle satellite cells against exhaustion via the Igfbp7-Akt-mTOR axis." Theranostics 10.14 (2020): 6448. https://doi.org/10.7150/thno.43577

The research reveals that exercise inhibits the Akt-mTOR pathway by upregulating IGFBP7, restricts mitochondrial metabolism in muscle satellite cells, maintains their proliferative potential, prevents exhaustion, and thereby promotes muscle hypertrophy and regeneration, providing potential therapeutic targets for muscle diseases.

4. He, Rui, et al. "IGFBP7 promotes endothelial cell repair in the recovery phase of acute lung injury." Clinical Science 138.13 (2024): 797-815. https://doi.org/10.1042/CS20240179

The study found that during the recovery period of acute lung injury, endothelial cells' IGFBP7 promotes endothelial proliferation through the FOS/YAP1 signaling pathway, which is crucial for tissue repair. This suggests that the targeted IGFBP7 treatment should take into account the specificity of the disease stage.

5. Li, Dandan, et al. "Cancer-associated fibroblast-secreted IGFBP7 promotes gastric cancer by enhancing tumor associated macrophage infiltration via FGF2/FGFR1/PI3K/AKT axis." Cell Death Discovery 9.1 (2023): 17. https://doi.org/10.1038/s41420-023-01336-x

The study found that in gastric cancer, IGFBP7 drives the polarization of tumor-associated macrophages towards the M2 type through the FGF2/FGFR1/PI3K/AKT axis, promoting tumor progression and being closely related to poor prognosis and remodeling of the tumor microenvironment.

Creative Biolabs: IGFBP7 Antibodies for Research

Creative Biolabs specializes in the production of high-quality IGFBP7 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom IGFBP7 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our IGFBP7 antibodies, custom preparations, or technical support, contact us at email.